Oura has postponed its planned initial public offering just as the smart-ring maker was preparing to price one of the fall’s most closely watched technology listings. The company cited uncertainty in the IPO market even though demand for the deal was reported to be strong. The reversal interrupts a launch that was expected to put Oura on the Nasdaq under the ticker OURA and turns attention from the company’s rapid expansion to the broader conditions facing businesses seeking public capital. Oura said it remains profitable and growing and can choose a later moment to proceed.
The preliminary prospectus filed with the Securities and Exchange Commission set out an offering of 50 million shares at an estimated price of $40 to $44 each. Oura itself planned to sell 13.5 million shares, while existing shareholders were offering the other 36.5 million. At the top of the range, the sale could have raised about $2.2 billion in gross proceeds for the company and selling holders. Eli Lilly had indicated interest in buying as much as $100 million of stock, and Dragoneer-affiliated funds had signaled possible demand for as much as $300 million, although those expressions were not binding.
The proposed listing was built on a sharp improvement in Oura’s financial profile. The company reported about $1.2 billion in revenue for the nine months ended June 30, compared with roughly $698 million a year earlier, while net income rose to approximately $61 million from about $2 million. Paid membership reached 5.7 million at the end of its fiscal year, according to the updated filing. Those figures had made the deal a prominent test of whether investors would value Oura primarily as a consumer-electronics company or as a subscription health platform built around long-term biometric data.
Prediction traders reacted forcefully to the postponement. The Polymarket contract for no Oura IPO before January 2027 traded near 93% in the latest snapshot, up about 92.7 percentage points over 24 hours. The broader event generated roughly $58,000 in activity during that period. That price reflects traders’ estimate of the contract outcome, not a company forecast, and a delay does not prove the listing has been abandoned. Oura could revive the transaction before year-end if volatility eases and the company and its underwriters judge that pricing conditions have improved.
The next signal will come from public filings and the underwriting group. A new prospectus amendment, a request to accelerate the registration statement or a formal pricing announcement would show that the offering is moving again. Until then, the postponement removes an imminent benchmark for the wearable-technology sector and delays the exit employees and early investors expected this week. It also tests the fall IPO window: if a profitable, fast-growing company with reported oversubscription prefers to wait, other issuers may be more cautious about accepting volatile pricing and rising long-term borrowing costs.
